vs
Side-by-side financial comparison of Ametek (AME) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.9B, roughly 1.2× Ametek). Zoetis runs the higher net margin — 25.3% vs 20.7%, a 4.6% gap on every dollar of revenue. On growth, Ametek posted the faster year-over-year revenue change (11.3% vs 3.0%). Over the past eight quarters, Ametek's revenue compounded faster (5.4% CAGR vs 4.4%).
AMETEK, Inc. is an American multinational conglomerate and global designer and manufacturer of electronic instruments and electromechanical devices with headquarters in the United States and over 150 sites worldwide.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
AME vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $2.4B |
| Net Profit | $399.4M | $603.0M |
| Gross Margin | 37.2% | 70.2% |
| Operating Margin | 26.7% | 31.9% |
| Net Margin | 20.7% | 25.3% |
| Revenue YoY | 11.3% | 3.0% |
| Net Profit YoY | 13.5% | 3.8% |
| EPS (diluted) | $1.74 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.9B | — | ||
| Q4 25 | $2.0B | $2.4B | ||
| Q3 25 | $1.9B | $2.4B | ||
| Q2 25 | $1.8B | $2.5B | ||
| Q1 25 | $1.7B | $2.2B | ||
| Q4 24 | $1.8B | $2.3B | ||
| Q3 24 | $1.7B | $2.4B | ||
| Q2 24 | $1.7B | $2.4B |
| Q1 26 | $399.4M | — | ||
| Q4 25 | $398.6M | $603.0M | ||
| Q3 25 | $371.4M | $721.0M | ||
| Q2 25 | $358.4M | $718.0M | ||
| Q1 25 | $351.8M | $631.0M | ||
| Q4 24 | $387.3M | $581.0M | ||
| Q3 24 | $340.2M | $682.0M | ||
| Q2 24 | $337.7M | $624.0M |
| Q1 26 | 37.2% | — | ||
| Q4 25 | 36.0% | 70.2% | ||
| Q3 25 | 36.3% | 71.5% | ||
| Q2 25 | 35.8% | 73.6% | ||
| Q1 25 | 36.1% | 72.0% | ||
| Q4 24 | 36.6% | 69.5% | ||
| Q3 24 | 36.0% | 70.6% | ||
| Q2 24 | 36.0% | 71.7% |
| Q1 26 | 26.7% | — | ||
| Q4 25 | 25.3% | 31.9% | ||
| Q3 25 | 25.8% | 37.0% | ||
| Q2 25 | 26.0% | 36.7% | ||
| Q1 25 | 26.3% | 36.5% | ||
| Q4 24 | 26.6% | 31.6% | ||
| Q3 24 | 26.1% | 36.6% | ||
| Q2 24 | 25.8% | 33.0% |
| Q1 26 | 20.7% | — | ||
| Q4 25 | 19.9% | 25.3% | ||
| Q3 25 | 19.6% | 30.0% | ||
| Q2 25 | 20.2% | 29.2% | ||
| Q1 25 | 20.3% | 28.4% | ||
| Q4 24 | 22.0% | 25.1% | ||
| Q3 24 | 19.9% | 28.6% | ||
| Q2 24 | 19.5% | 26.4% |
| Q1 26 | $1.74 | — | ||
| Q4 25 | $1.73 | $1.37 | ||
| Q3 25 | $1.60 | $1.63 | ||
| Q2 25 | $1.55 | $1.61 | ||
| Q1 25 | $1.52 | $1.41 | ||
| Q4 24 | $1.67 | $1.29 | ||
| Q3 24 | $1.47 | $1.50 | ||
| Q2 24 | $1.45 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $481.3M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $10.9B | $3.3B |
| Total Assets | $16.3B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $481.3M | — | ||
| Q4 25 | $458.0M | — | ||
| Q3 25 | $439.2M | $2.1B | ||
| Q2 25 | $619.7M | $1.4B | ||
| Q1 25 | $399.0M | $1.7B | ||
| Q4 24 | $374.0M | $2.0B | ||
| Q3 24 | $396.3M | $1.7B | ||
| Q2 24 | $396.6M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $10.9B | — | ||
| Q4 25 | $10.6B | $3.3B | ||
| Q3 25 | $10.5B | $5.4B | ||
| Q2 25 | $10.4B | $5.0B | ||
| Q1 25 | $10.0B | $4.7B | ||
| Q4 24 | $9.7B | $4.8B | ||
| Q3 24 | $9.6B | $5.2B | ||
| Q2 24 | $9.3B | $5.0B |
| Q1 26 | $16.3B | — | ||
| Q4 25 | $16.1B | $15.5B | ||
| Q3 25 | $16.2B | $15.2B | ||
| Q2 25 | $15.3B | $14.5B | ||
| Q1 25 | $14.9B | $14.1B | ||
| Q4 24 | $14.6B | $14.2B | ||
| Q3 24 | $14.8B | $14.4B | ||
| Q2 24 | $14.8B | $14.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.21× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.22× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $584.3M | $893.0M | ||
| Q3 25 | $440.9M | $938.0M | ||
| Q2 25 | $359.1M | $486.0M | ||
| Q1 25 | $417.5M | $587.0M | ||
| Q4 24 | $550.0M | $905.0M | ||
| Q3 24 | $487.2M | $951.0M | ||
| Q2 24 | $381.4M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | $527.3M | $732.0M | ||
| Q3 25 | $420.0M | $805.0M | ||
| Q2 25 | $329.8M | $308.0M | ||
| Q1 25 | $394.5M | $438.0M | ||
| Q4 24 | $498.3M | $689.0M | ||
| Q3 24 | $460.9M | $784.0M | ||
| Q2 24 | $360.0M | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | 26.4% | 30.7% | ||
| Q3 25 | 22.2% | 33.5% | ||
| Q2 25 | 18.5% | 12.5% | ||
| Q1 25 | 22.8% | 19.7% | ||
| Q4 24 | 28.3% | 29.7% | ||
| Q3 24 | 27.0% | 32.8% | ||
| Q2 24 | 20.8% | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | 2.9% | 6.7% | ||
| Q3 25 | 1.1% | 5.5% | ||
| Q2 25 | 1.6% | 7.2% | ||
| Q1 25 | 1.3% | 6.7% | ||
| Q4 24 | 2.9% | 9.3% | ||
| Q3 24 | 1.5% | 7.0% | ||
| Q2 24 | 1.2% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.47× | 1.48× | ||
| Q3 25 | 1.19× | 1.30× | ||
| Q2 25 | 1.00× | 0.68× | ||
| Q1 25 | 1.19× | 0.93× | ||
| Q4 24 | 1.42× | 1.56× | ||
| Q3 24 | 1.43× | 1.39× | ||
| Q2 24 | 1.13× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AME
| Electronic Instruments | $1.3B | 66% |
| Electromechanical | $663.9M | 34% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
